$5.10
Value $226M
BIOA and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$5.10
Value $226M
$278.70
Value $672B
BioAge Labs (BIOA) has a market value of $226M and Johnson & Johnson (JNJ) $672B. Over the last year, with dividends, BIOA moved -34.6% and JNJ +45.4%. Dividend yield: BIOA none, JNJ 1.89%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
BIOA$226M
JNJ$672B
JNJ is 2,967 times BIOA
Revenue, 12 months
BIOA$8.6M
JNJ$99.3B
JNJ is 11,552 times BIOA
Net income, 12 months
BIOA-$108M
JNJ$16.1B
Operating margin
BIOA-1,401.8%
JNJ–
ROIC
BIOA-28.7%
JNJ12.4%
41.1 points apart
P/E
BIOA–
JNJ41.7
Dividend yield
BIOA0.0%
JNJ1.9%
1.9 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
BIOA-34.6%
JNJ+45.4%
| Period | BIOAWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | -34.6%Price -34.6% | +45.4%Price +42.2% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
BIOABioAge LabsJNJJohnson & Johnson
| Price | $5.10 | $278.70 |
|---|---|---|
| Market value | $226M | $672B |
| Enterprise value (EV) | – | $699B |
| P/E | – | 41.7 |
| P/E, 5-year median | – | 21.9 |
| P/B | 0.7 | 8.2 |
| EV/EBIT | – | 39.4 |
| Free cash flow yield | – | 3.1% |
| Revenue, 12 months | $8.6M | $99.3B |
|---|---|---|
| Net income, 12 months | -$108M | $16.1B |
| Free cash flow, 12 months | -$103M | $20.6B |
| Earnings per share, 12 months | -$2.55 | $6.59 |
| Revenue growth, year on year | – | 6.1% |
| Revenue growth a year, past | – | +2.7%over 5 years |
| EPS growth a year, past | – | +14.9%over 5 years |
| Gross margin | – | 67.6% |
|---|---|---|
| Operating margin | -1,401.8% | – |
| Net margin | -1,253.6% | 16.2% |
| ROIC | -28.7% | 12.4% |
| ROE | -32.7% | 19.7% |
| Cash | $284M | $17.2B |
|---|---|---|
| Total debt | $2.7M | $44.7B |
| Net debt / EBITDA | – | 1.1 |
| Interest cover | -913.2× | 18.0× |
| Dividend yield | – | 1.9% |
|---|---|---|
| Dividend per share, 12 months | – | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | – | 0.9% |
| Shareholder yield | – | 2.8% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($672B) is about 2,967.4 times BioAge Labs ($226M), at today's prices.
Since November 14, 2025, BIOA's price moved -34.6% and JNJ's +42.2%. With dividends: BIOA -34.6% (-34.6% a year), JNJ +45.4% (+45.4% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for BioAge Labs and 1.89% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.
Over the last twelve months, the net margin was -1,253.6% for BioAge Labs and 16.2% for Johnson & Johnson, and the operating margin -1,401.8% and –. Revenue was $8.6M and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.